JP2019529416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529416A5 JP2019529416A5 JP2019514735A JP2019514735A JP2019529416A5 JP 2019529416 A5 JP2019529416 A5 JP 2019529416A5 JP 2019514735 A JP2019514735 A JP 2019514735A JP 2019514735 A JP2019514735 A JP 2019514735A JP 2019529416 A5 JP2019529416 A5 JP 2019529416A5
- Authority
- JP
- Japan
- Prior art keywords
- klrg1
- antibody
- composition according
- depleting agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395551P | 2016-09-16 | 2016-09-16 | |
| US62/395,551 | 2016-09-16 | ||
| PCT/US2017/051776 WO2018053264A2 (en) | 2016-09-16 | 2017-09-15 | Klrg1 depletion therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529416A JP2019529416A (ja) | 2019-10-17 |
| JP2019529416A5 true JP2019529416A5 (enExample) | 2020-09-17 |
Family
ID=61619243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514735A Pending JP2019529416A (ja) | 2016-09-16 | 2017-09-15 | Ｋｌｒｇ１枯渇療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190194333A1 (enExample) |
| EP (1) | EP3512553A4 (enExample) |
| JP (1) | JP2019529416A (enExample) |
| CN (1) | CN110300598A (enExample) |
| AU (1) | AU2017326003A1 (enExample) |
| CA (1) | CA3036835A1 (enExample) |
| WO (1) | WO2018053264A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210002373A1 (en) * | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
| EP3852779A4 (en) * | 2018-09-17 | 2022-06-08 | Abcuro, Inc. | ANTI-KLRG1 ANTIBODIES |
| WO2020210512A1 (en) | 2019-04-09 | 2020-10-15 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
| WO2022056289A1 (en) * | 2020-09-11 | 2022-03-17 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
| CN113058029A (zh) * | 2021-03-18 | 2021-07-02 | 西安交通大学 | 胶原凝集素-11在制备防治泌尿系统感染的药物中的应用 |
| JP2024528877A (ja) | 2021-07-26 | 2024-08-01 | アブクロ，インク． | キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）枯渇性抗体 |
| CN120569402A (zh) * | 2022-10-25 | 2025-08-29 | 布里格姆妇女医院 | Klrb1结合剂及其使用方法 |
| WO2025147544A1 (en) | 2024-01-02 | 2025-07-10 | Abcuro, Inc. | Methods of treating inclusion body myositis (ibm) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0672142T3 (da) * | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US8637084B2 (en) * | 2009-07-14 | 2014-01-28 | Asahi Kasei Medical Co., Ltd. | Treatment method for epithelial cancerous organism |
| JP2012025694A (ja) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Kuraray Medical Co Ltd | 癌治療剤 |
| SG10201902380SA (en) * | 2013-06-25 | 2019-04-29 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| EP3190415B1 (en) * | 2014-07-25 | 2019-05-01 | Riken | Memory invariant nkt cell marker |
| EP3471539A4 (en) * | 2016-06-03 | 2020-02-26 | The Brigham and Women's Hospital | KLRG1 SIGNALING THERAPY |
-
2017
- 2017-09-15 CA CA3036835A patent/CA3036835A1/en not_active Abandoned
- 2017-09-15 US US16/327,576 patent/US20190194333A1/en not_active Abandoned
- 2017-09-15 AU AU2017326003A patent/AU2017326003A1/en not_active Abandoned
- 2017-09-15 EP EP17851602.7A patent/EP3512553A4/en not_active Withdrawn
- 2017-09-15 CN CN201780069194.2A patent/CN110300598A/zh not_active Withdrawn
- 2017-09-15 WO PCT/US2017/051776 patent/WO2018053264A2/en not_active Ceased
- 2017-09-15 JP JP2019514735A patent/JP2019529416A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529416A5 (enExample) | ||
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| Claus et al. | The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy | |
| ES3053745T3 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| US10688180B2 (en) | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer | |
| KR102787984B1 (ko) | 항-lag3 항체 및 그 사용 | |
| CA2887027C (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer | |
| US20170015758A1 (en) | Compositions And Methods For Modulating And Redirecting Immune Responses | |
| CN113164598A (zh) | 双特异性抗cd28 x抗cd22抗体以及其用途 | |
| JP6715491B2 (ja) | 免疫チェックポイント制御剤の副作用低減方法 | |
| JP7170331B2 (ja) | 固形及び血液癌の治療のための併用療法 | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| EP3694552A1 (en) | Anti-lap antibodies and uses thereof | |
| US10494433B2 (en) | Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma | |
| US20190309066A1 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| JP2021520201A (ja) | 抗ｃｄ２７抗体およびその使用 | |
| CN114206919A (zh) | 靶向taci的抗体和嵌合抗原受体 | |
| WO2021080920A2 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| US20230183342A1 (en) | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections | |
| JP2025063054A (ja) | ガンマデルタｔ細胞集団の選択的生体内増殖方法及びその組成物 | |
| JP2024097985A (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| WO2021263085A2 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| EP3765519B1 (en) | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy | |
| Theofilidis | The Goldilocks Zone: Optimizing T Cell Engager Affinity, Kinetics and Architecture for Anti-Tumor Efficacy | |
| CA3191224A1 (en) | Multispecific binding compounds that bind to pd-l1 |